Trioar Biotechnology Overview

  • Year Founded
  • 2021

Year Founded

  • Status
  • Private

  • Employees
  • 30

Employees

  • Latest Deal Type
  • Series C

  • Latest Deal Amount
  • $24.5M

  • Investors
  • 27

Trioar Biotechnology General Information

Description

Developer of antibody-based therapeutics designed to treat cancer, inflammation, and autoimmunity. The company's proprietary trio technology platform utilizes novel linker-payloads and target detection mechanisms to improve the therapeutic index of anticancer agents, enabling healthcare companies to develop medicines that specifically target cancer cells while simultaneously reducing toxicity and improving efficacy.

Contact Information

Website
www.trioar.co.kr
Ownership Status
Privately Held (backing)
Financing Status
Venture Capital-Backed
Corporate Office
  • 361-17, Gapcheon-ro, Yuseong-gu
  • Room 403
  • Daejeon
  • South Korea
+82
Primary Industry
Drug Discovery
Other Industries
Biotechnology
Vertical(s)
HealthTech, Life Sciences, Oncology
Corporate Office
  • 361-17, Gapcheon-ro, Yuseong-gu
  • Room 403
  • Daejeon
  • South Korea
+82

Trioar Biotechnology Timeline

2023202420252026
Financing RoundCaptured Employee CountEstimated Employee Growth

Want detailed data on 11M+ companies?

What you see here scratches the surface

Request a free trial

Want to dig into this profile?

We’ll help you find what you need

Learn more

Trioar Biotechnology Valuation & Funding

Deal Type Date Amount Raised to Date Post-Val Status Stage
9. Later Stage VC (Series C) 22-Oct-2026 $24.5M Completed Pre-Clinical Trials
8. Accelerator/Incubator 06-Jul-2026 Completed Pre-Clinical Trials
7. Accelerator/Incubator 01-Aug-2025 Completed Pre-Clinical Trials
6. Early Stage VC (Series B) 17-Jul-2025 Completed Pre-Clinical Trials
5. Early Stage VC (Series A) 23-May-2023 Completed Pre-Clinical Trials
4. Seed Round 03-Mar-2022 Completed Pre-Clinical Trials
3. Angel (individual) Completed Pre-Clinical Trials
2. Accelerator/Incubator Completed Pre-Clinical Trials
1. Accelerator/Incubator Completed Pre-Clinical Trials
To view Trioar Biotechnology’s complete valuation and funding history, request access »

VC Exit Predictor

See how our proprietary methodology utilizes historical data sets to synthesize the likelihood of an acquisition, IPO, or no exit event. Get a detailed look at the calculations behind our predictions.

Opportunity Score

Calculated using Exit Type probabilities, the company’s stage, and PitchBook’s historical returns data.

Exit Type

Evaluates the likelihood of a successful exit for investors, and the most likely exit type.

Request a free trial

Trioar Biotechnology Signals

Growth Rate

Weekly
Growth
Weekly Growth

Size Multiple

Median
Size Multiple

Key Data Points

Similarweb Unique Visitors

Majestic Referring Domains

PitchBook’s non-financial metrics help you gauge a company’s traction and growth using web presence and social reach.

Request a free trial

Trioar Biotechnology Investors (27)

Investor Name Investor Type Holding Investor Since Participating Rounds
DS Asset Management Asset Manager Minority
HB Investment Venture Capital Minority
Honeypot Ventures Venture Capital Minority
Korea Development Bank VC-Backed Company Minority
Tech Incubator Program for Startup Accelerator/Incubator
You’re viewing 5 of 27 investors. Get the full list »

Ready to get started?

Request a free trial

Trioar Biotechnology FAQs

  • When was Trioar Biotechnology founded?

    Trioar Biotechnology was founded in 2021.

  • Where is Trioar Biotechnology headquartered?

    Trioar Biotechnology is headquartered in Daejeon, South Korea.

  • What is the size of Trioar Biotechnology?

    Trioar Biotechnology has 30 total employees.

  • What industry is Trioar Biotechnology in?

    Trioar Biotechnology’s primary industry is Drug Discovery.

  • Is Trioar Biotechnology a private or public company?

    Trioar Biotechnology is a Private company.

  • What is Trioar Biotechnology’s current revenue?

    The current revenue for Trioar Biotechnology is .

  • How much funding has Trioar Biotechnology raised over time?

    Trioar Biotechnology has raised $57.5M.

  • Who are Trioar Biotechnology’s investors?

    DS Asset Management, HB Investment, Honeypot Ventures, Korea Development Bank, and Tech Incubator Program for Startup are 5 of 27 investors who have invested in Trioar Biotechnology.

Data Transparency

  • Meet our data hygiene team

    Discover how our experts ensure you’re getting the most accurate financial data in the industry.

    Read more

  • How PitchBook sources data

    Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.

    Discover our process